Welcome to our dedicated page for SOLIGENIX SEC filings (Ticker: SNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Soligenix, Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical issuer developing rare-disease therapeutics and public health vaccine candidates. Form 8-K reports disclose clinical and regulatory events for HyBryte in cutaneous T-cell lymphoma and SGX945 (dusquetide) in Behçet's Disease, including trial-result announcements, orphan drug designations and corporate progress updates.
Registration statements and material-event filings describe Soligenix's capital structure, including common stock, warrants, preferred stock and at-the-market or public offering activity. The filing record also covers Nasdaq continued-listing compliance, material agreements, governance matters, operating and financial results, risk factors and shareholder voting matters tied to its drug-development pipeline.
Form 4 Filing Details: Jerome B. Zeldis, Director of Soligenix (SNGX), reported the acquisition of stock options on June 20, 2025. The insider was granted 17,647 stock options with an exercise price of $1.70 per share.
The options have a 10-year term expiring on June 20, 2035, and will vest in four equal installments on:
- September 20, 2025
- December 20, 2025
- March 20, 2026
- June 20, 2026
This equity-based compensation grant aligns the director's interests with shareholders through long-term stock ownership potential. The filing was reported within the required SEC timeline, demonstrating compliance with Section 16(a) reporting obligations.
Form 4 filing reveals that Robert J. Rubin, Director at Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:
- Granted 17,647 stock options to purchase common stock
- Exercise price set at $1.70 per share
- Options expire on June 20, 2035
- Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026
This equity compensation grant aligns the director's interests with shareholders through a standard 10-year term and quarterly vesting schedule over one year. The transaction was reported in compliance with SEC Section 16 requirements for insider trading disclosure.
Form 4 filing reveals that Diane L. Parks, Director at Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:
- Granted 17,647 stock options to purchase common stock
- Exercise price set at $1.70 per share
- Options expire on June 20, 2035
- Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026
This stock option grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity incentives. The 10-year exercise period provides significant time value for these options.
Soligenix has filed a Form S-8 to register securities under its 2025 Equity Incentive Plan. The company, headquartered in Princeton, New Jersey, is classified as both a non-accelerated filer and a smaller reporting company.
Key filing incorporations include:
- Annual Report on Form 10-K for FY2024 (filed March 21, 2025)
- Q1 2025 Form 10-Q (filed May 9, 2025)
- Recent Form 8-K filings from February, March, and June 2025
The registration includes comprehensive indemnification provisions for directors and officers under Delaware law, including protection against personal liability for fiduciary duty breaches, except in cases of:
- Breach of duty of loyalty
- Acts not in good faith or involving intentional misconduct
- Unlawful dividend payments or stock repurchases
- Improper personal benefit transactions